术前放疗在早期乳腺癌中诱导分子与免疫调节:YOUNGSTER试验结果
YOUNGSTER探索性研究纳入20例未接受过治疗的早期乳腺癌患者,给予术前放疗加强(5×2.67 Gy/次)后行穿刺活检,部分患者2-8周后手术。结果显示放疗后数天内增殖基因和Ki67显著下调、DNA损伤增加、巨噬细胞标志物上调;术后样本中适应性免疫标志物及14基因免疫球蛋白特征显著上调。提示术前放疗可能作为免疫治疗的有效引物。
要点
- 术前放疗后3-5天即见增殖基因、PAM50增殖特征及Ki67显著下调。
- 术后2-8周样本显示适应性免疫标志物和14基因免疫球蛋白特征显著上调。
- 术前放疗可能作为免疫治疗引物,尤其适用于高风险亚型。
核心结论
- 术前放疗在早期乳腺癌中诱导早期增殖抑制和DNA损伤,随后数周内出现适应性免疫激活。
- 术前放疗可能作为免疫治疗的有效引物,支持联合治疗策略。
研究设计与样本
- YOUNGSTER探索性研究纳入20例适合保乳手术且未接受过治疗的早期乳腺癌患者。
- 术前给予放疗加强5×2.67 Gy/次后行穿刺活检,患者4周(2-8周)后手术或接受新辅助治疗。
- 采用192基因panel分析基因表达,并行Ki67和CD68免疫组化、肿瘤浸润淋巴细胞定量及γH2AX染色评估DNA损伤。
主要发现
- 基线PAM50亚型分布为luminal A 35%、luminal B 25%、HER2富集型20%、基底样型20%。
- 放疗后早期样本显示增殖基因、PAM50增殖特征和Ki67免疫组化染色显著下调,DNA损伤增加,巨噬细胞标志物上调。
- 术后样本(放疗后2-8周,n=13)显示适应性免疫标志物显著上调,14基因免疫球蛋白特征增加。
临床怎么用
- 术前放疗可在数天内抑制肿瘤增殖并增加DNA损伤,数周后激活适应性免疫。
- 对于高风险亚型早期乳腺癌,可考虑术前放疗联合免疫治疗的策略。
局限性
- 本研究为探索性研究,样本量小(20例),术后样本仅13例。
- 原文未报告统计学显著性检验的具体P值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The impact of preoperative radiation therapy (RT) on early-stage breast cancer (BC) is underexplored but may significantly improve outcomes and offer new therapeutic strategies. The YOUNGSTER study aimed to characterize the molecular changes induced by preoperative RT across BC subtypes: luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, and basal-like. METHODS AND MATERIALS: This exploratory study enrolled 20 patients with early-stage BC who were eligible for breast-conserving surgery and had not received prior treatment. Biological changes were assessed between baseline, 3 to 5 days post-RT, and surgical samples. A preoperative RT boost (5 × 2.67 Gy/fraction) was administered, followed by a core needle biopsy. Patients then proceeded to either surgery 4 weeks (2-8 weeks) after RT or neoadjuvant therapy. Gene expression was analyzed using a 192-gene panel, alongside immunohistochemistry for Ki67 and CD68, tumor-infiltrating lymphocytes quantification, and γH2AX staining for DNA damage assessment. RESULTS: At baseline, PAM50 subtype distribution was luminal A (35%), luminal B (25%), HER2-enriched (20%), and basal-like (20%). Early post-RT samples showed significant downregulation of proliferation genes, PAM50 proliferation signature, and Ki67 immunohistochemistry staining, increased DNA damage, and macrophage marker upregulation. In primary surgery samples (2-8 weeks post-RT) (n = 13), adaptive immune markers showed significant upregulation, along with a 14-gene immunoglobulin signature increase. CONCLUSIONS: Preoperative RT induces early and late biological changes in BC, with initial effects on proliferation reduction and DNA damage within days, followed by adaptive immune activation within weeks. RT may serve as an effective primer for immunotherapy, especially in higher-risk subtypes, supporting the potential for combinatorial approaches in BC management.
引用
- Gomà C, Mollà M, Oses G, et al. Preoperative Radiation Therapy-Induced Molecular and Immune Modulation in Early-Stage Breast Cancer: Results From the YOUNGSTER trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 40754202. doi:10.1016/j.ijrobp.2025.07.1443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。